Zobrazeno 1 - 10
of 146
pro vyhledávání: '"K Mangan"'
Publikováno v:
Leukemia Research Reports, Vol 21, Iss , Pp 100408- (2024)
Near early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare hematologic malignancy, for which second line therapeutic options are limited. T-cell leukemias are also rarely associated with leukemia cutis, which is more often seen in l
Externí odkaz:
https://doaj.org/article/fe8d38475e0d44a1b5ca231ebee32d91
Autor:
Ibrahim Aldoss, Parastou Tizro, Davsheen Bedi, James K. Mangan, Mary C. Clark, David Spencer, Joo Y. Song, Sindhu Cherian, Raju Pillai, Young Kim, Nitin Mahajan, Ketevan Gendzekhadze, Mike James, Kenneth Jacobs, Jan Davidson-Moncada, Stephen J. Forman, Huan-You Wang, Michelle Afkhami
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/0947cc1b366b42d5b7abf59f6ae225a9
Autor:
Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K. Mangan, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheu
Externí odkaz:
https://doaj.org/article/12ab6b3c9513426f81af28505c83a39c
Publikováno v:
Case Reports in Hematology, Vol 2022 (2022)
Acute myeloid leukemia (AML) is associated with particularly poor outcomes in the elderly population, in whom the disease is most prevalent. BCL-2 has been identified as an antiapoptotic protein and promotes survival of leukemia stem cells. Recently,
Externí odkaz:
https://doaj.org/article/e389df2cd5b34444b03a87c04eeb77f5
Autor:
Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten, Albert Torri
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 3, Pp 339-352 (2019)
Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional
Externí odkaz:
https://doaj.org/article/c4ff01ffaea0496db79cb29f61362bca
Autor:
Matthew P. Connor, Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar I. Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, Alison Carulli, Christopher Catania, Jacqueline Smith, Lauren Hollander, Alexis M. Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle V. Frey
Publikováno v:
Transplantation and Cellular Therapy. 29:113-118
Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) in patients with active, chemotherapy-refractory myeloid disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5dc190078edd5f8225903761044691
https://doi.org/10.1016/j.jtct.2022.10.027
https://doi.org/10.1016/j.jtct.2022.10.027
Autor:
Vibeke Strand, Laure Gossec, Clare W. J. Proudfoot, Chieh-I Chen, Matthew Reaney, Sophie Guillonneau, Toshio Kimura, Janet van Adelsberg, Yong Lin, Erin K. Mangan, Hubert van Hoogstraten, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monoth
Externí odkaz:
https://doaj.org/article/0f4f3986999d4d779a961f01dcdc58ab
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e161-e184
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5119cb54cdce7aacfb9028d7ab5d8934
https://doi.org/10.1016/j.clml.2021.09.002
https://doi.org/10.1016/j.clml.2021.09.002
Autor:
Craig W. Freyer, Alison Carulli, Shannon Gier, Alex Ganetsky, Colleen Timlin, Mindy Schuster, Daria Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Keith Pratz, Jacqueline Smith, Edward A. Stadtmauer, Alison W. Loren
Publikováno v:
Leukemia & Lymphoma. 63:1925-1933
Patients undergoing haploidentical or mismatched unrelated donor (haplo/MMUD) allogeneic hematopoietic cell transplantation (alloHCT) receiving post-transplant cyclophosphamide (PTCy) are at high risk of cytomegalovirus (CMV) infection. Experience wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31ae436ac3c845212c41a5c591a38da1
https://doi.org/10.1080/10428194.2022.2042686
https://doi.org/10.1080/10428194.2022.2042686
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive postthymic T-cell neoplasm with an associated survival time of 1 year when left untreated. Current standard of care for T-PLL is with alemtuzumab, followed by allogeneic or autologous st
Externí odkaz:
https://doaj.org/article/f44fda4fea754706baef9ff8756c496f